VMX-C001

Phase 3Small molecule

VVarmX B.V.

VMX-C001 is one of 5 small molecule programs targeting Blood Loss, Surgical. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Blood Loss, SurgicalRecruiting

AnticoagulantCompleted

Blood Loss, SurgicalPhase 3

Recruiting

AnticoagulantPhase 1

Completed

Competition

Competitive Landscape

3 competitors in Anticoagulant

#DrugCompanyPhaseTrials

Xarelto

WWim Janssens

Approved

13 2

Lovenox

Sanofi

Phase 1

3 3

VMX-C001

VVarmX B.V.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Anticoagulant

NCT06517563

Q1 2031

Phase 3Recruiting

Blood Loss, Surgical

NCT07288489

Clinical

Trials by Indication[1]

Anticoagulant2 trials

Effects of VMX-C001 on the Anticoagulant Effect of Different Forms of Heparin

Active, not recruiting·VVarmX B.V.·Phase 1·NCT06517563·16 enrolled

Study of Intravenous VMX-C001 in Healthy Subjects and in Combination With Selected Direct Oral Anticoagulants in Healthy Older Subjects

Completed·VVarmX B.V.·Phase 1·NCT05152420·105 enrolled

Coagulation Disorder1 trial

A Randomised, Double-Blind, Placebo-Controlled, Single Dose Trial Evaluating Different Doses of Intravenously Administered VMX-C001 and to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of VMX-C001 in Healthy Subjects (Part 1) and in Combination With a Selected FXa Direct Oral Anticoagulant (DOAC) in Healthy Older Subjects (Part 2)

Completed·VVarmX B.V.·Phase 1·NCT06372483·40 enrolled

Blood Loss, Surgical1 trial

A Phase 3 Prospective Randomised Clinical Trial of VMX-C001 vs Usual Pharmacological Care in Patients Receiving a FXa Direct Oral Anticoagulant (FXa DOAC) Who Require Urgent Surgery or Other Invasive Procedure That is Associated With a High Risk of Bleeding, With or Without Planned Administration of Heparin (EQUILIBRIX-S)

Recruiting·VVarmX B.V.·Phase 3·NCT07288489·800 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for VMX-C001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VMX-C001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VMX-C001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — VarmX B.V. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: VVarmX B.V.

VMX-C001

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2031

Trials by Indication[1]

Anticoagulant2 trials

Coagulation Disorder1 trial

Blood Loss, Surgical1 trial

References

Drug Info

Quick Facts

Related News